Table 3.
Summary of reported cardiotoxicity in adult and pediatric populations associated with chimeric antigen receptor T-Cell therapy.
| Maude et al., 2014 [30] | Neelapu et al. (ZUMA-1) [32] | Fitzgerald et al., 2017 [28] | Maude et al. (ELIANA), 2018 [31] | Burstein et al., 2018 [27] | Schuster et al. (JULIET) [33] | Alvi et al., 2019 [21] | Lefebvre et al., 2020 [29] | Shalabi et al., 2020 [34] | Ganatra et al., 2020 [20] | Brammer et al., 2021 [26] | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | 30 | 101 | 39 | 75 | 98 | 93 | 137 | 145 | 52 | 187 | 102 |
| Population | pediatric | adult | pediatric | pediatric | pediatric | adult | adult | adult | pediatric | adult | adult |
| Hypotension (Inotropic Support or Shock) | 27% | 14% | 33% | 17% | 21% | 9% | 4% | 22.7% | 24.3% | 2.6% | |
| Left Ventricular Systolic Dysfunction | 4% | 10% | 6% | 11.5% | 6.4% | ||||||
| Pulmonary Edema | 6.7% | 4% | |||||||||
| Cardiac Arrest | 1% | 4% | 2% | ||||||||
| Heart Failure | 2.7% | 6% | 15% | 3.2% | 1.1% | ||||||
| Non-fatal Acute Coronary Syndrome | 1.4% | ||||||||||
| Cardiovascular Death | 1% | 4% | 1.4% | 1.6% | |||||||
| New or Worsening Arrhythmia | 3.6% | 9% (7.6% AFib) |
7% | 12.2% | |||||||
| Sinus Tachycardia | 39% | 4% | 11% | 4.4% | 69.2% | ||||||
| New or Worsening Cardiomyopathy | 10.3% | ||||||||||
| ST-Segment Changes | 6% | ||||||||||
| Biomarker Abnormalities | NT-proBNP (92%) Lactate (79%) Mixed venous saturation (52%) |
Troponin elevation (21%) NT-proBNP (4%) |